Innate Pharma S.A.
IPHA
NASDAQ·Healthcare·Biotechnology·Mkt cap $195.3M
$2.08
▼ -1.42%
P/E
-1.56
Mkt Cap
$195.3M
52-Wk Range
$1.17–$2.71
52-Week Range
$1.17 - $2.71
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 2.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary antibody discovery and engineering platform
- Strategic partnerships with pharmaceutical leaders (AstraZeneca, Sanofi, Novo Nordisk)
- Diverse pipeline targeting multiple immunological pathways
- Expertise in innate immunity and immune checkpoint modulation
Bear Case
1 risk
- Average volatility.
Growth
Strong growth ahead
Clinical advancement of Monalizumab Phase III program for solid tumors
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Strong
+18.2% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying IPHA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Sep 17, 2026
Most recent quarter reported revenue of $-2.4M (-851% YoY). Reported EPS of -$0.33.
Reported EPS · last 4Q
Q4 25
-$0.33
Q2 25
-$0.29
Q4 24
-$0.35
Q2 24
-$0.36
Revenue trend · last 8Q
—
—
-14%
+99%
-65%
-98%
-61%
-851%
Q2 22
Q4 22
Q2 23
Q4 23
Q2 24
Q4 24
Q2 25
Q4 25
$48.4M
$9.7M
$41.4M
$19.4M
$14.5M
$323.6K
$5.7M
-$2.4M
Margins · last 8Q
Gross
—
Operating
—
Profit
—
Wall Street consensus
4 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: BTIG · Aug 12, 2026
vs Industry
How IPHA stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related